Cytosorbents (NASDAQ:CTSO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Get Rating) in a research report report published on Friday morning, Benzinga reports. They currently have a $5.50 target price on the medical research company’s stock.

Separately, StockNews.com raised Cytosorbents from a sell rating to a hold rating in a research note on Friday.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $3.28 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.47 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $2.87 and its two-hundred day moving average is $2.02. The company has a market cap of $142.99 million, a P/E ratio of -4.37 and a beta of 0.77. Cytosorbents has a 12 month low of $1.03 and a 12 month high of $4.59.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of CTSO. Raymond James Financial Services Advisors Inc. grew its holdings in Cytosorbents by 21.3% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 57,684 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 10,141 shares during the period. Bank of Montreal Can acquired a new position in Cytosorbents during the first quarter valued at approximately $70,000. Renaissance Technologies LLC acquired a new position in Cytosorbents during the first quarter valued at approximately $271,000. Goldman Sachs Group Inc. boosted its holdings in shares of Cytosorbents by 129.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,877 shares of the medical research company’s stock valued at $954,000 after buying an additional 168,712 shares during the period. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of Cytosorbents in the first quarter valued at approximately $28,000. 34.04% of the stock is owned by institutional investors.

Cytosorbents Company Profile

(Get Rating)

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.